Ceragenix to Present at Rodman & Renshaw Third Annual Global Healthcare Conference

DENVER, May 1, 2006 -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a biopharmaceutical company focused on infectious disease and dermatology, today announced that Steven Porter, Chairman and CEO of Ceragenix, will present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Monday, May 15 at 11:15 AM UTC (5:15 AM EST) in the Zephyr Salon of the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. The presentation will be web cast and available at http://wsw.com/webcast/rrshq8/cgxp.ob/ . The web cast will be archived until August 15, 2006.

Mr. Porter will provide a brief corporate overview and discuss the company's novel anti-infective drugs--based on its proprietary class of compounds, Ceragenins (formerly known as CSAs)--and its Barrier Repair Technology. Ceragenix recently received 510K clearance from the U.S. Food and Drug Administration for its EpiCeram(R) Skin Barrier Emulsion to improve dry skin conditions and to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis, and other dry skin conditions by maintaining a moist wound and skin environment.

About CERAGENIX

Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings and as therapeutics for antibiotic-resistant organisms.

Ceragenix further owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the Regents of the University of California, is the platform for the development of two prescription topical creams-EpiCeram(R) and NeoCeram(R). For additional information on Ceragenix, please visit www.ceragenix.com.

CONTACT:  Ceragenix Pharmaceuticals, Inc.
          Steven Porter
          (720) 946-6440

          Financial Dynamics 
          Robert Stanislaro
          (212) 850-5657 
          ceragenix@fd-us.com